Gene

MDM2

MDM2 proto-oncogene

Explore in graph →CI-GENE-00012270HGNC:6973 ENSG00000135679 NCBI 4193 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (9)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–9 of 9 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
MDM2 Amplification3
HDM2 Inhibitor MK-8242	Liposarcoma	Predictive	C	Supports Sensitivity Response	4	submitted	EID5518

Cohorts

Alteration frequency by cohort (26)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

gdcObserved26 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Adrenocortical Carcinoma TCGA-ACC	Adrenal Cortical CarcinomaALIAS

Literature

Linked publications (3)

25 per page, newest first.

pubmedPublishedShowing 1–3 of 3 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.
· Br J Cancer · 2015 · PMID 25668009 · validated civic_curation pubmed
Genetic Variants in the p14ARF/MDM2/TP53 Pathway Are Associated with the Prognosis of Esophageal Squamous Cell Carcinoma Patients Treated with Radical Resection.
· PLoS One · 2016 · PMID 27414035 · validated civic_curation pubmed
Correlation of TP53 and MDM2 genotypes and clinical outcome in platinum-treated head and neck cancer patients with more than 10 years' follow-up.
· Int J Biol Markers · 2016 · PMID 26916894 · validated civic_curation pubmed

MDM2 Amplification + MET D1010HMDM2 MET1
Crizotinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	3	submitted	EID11374 A 76-year old female (former light smoker) diagnosed with metastatic squamous lung carcinoma was found to have MET D1010H and MDM2 mutation following mutation analysis. She was originally treated with… (full text at CIViC) PMID 25898965 · Mendenhall et al., 2015 · Open in CIViC	civic

MDM2 Amplification + MET D1010HMDM2 MET1

Crizotinib

Lung Non-Small Cell CarcinomaCURATED_BROADER

Predictive

Supports Sensitivity Response

submitted

EID11374

A 76-year old female (former light smoker) diagnosed with metastatic squamous lung carcinoma was found to have MET D1010H and MDM2 mutation following mutation analysis. She was originally treated with… (full text at CIViC)

PMID 25898965 · Mendenhall et al., 2015 · Open in CIViC

civic

MDM2 EXPRESSION3
(prognostic)	Pleural Malignant MesotheliomaALIAS	Prognostic	B	Supports Poor Outcome	3	accepted	EID828 72 patients with malignant pleural mesothelioma were analyzed, MDM2 immunoexpression was assessed in 65 patients. MDM2 mRNA and protein expression correlated with poor OS and PFS for patients treated … (full text at CIViC) PMID 25668009 · Walter et al., 2015 · Open in CIViC	civic
Navtemadlin	Malignant Ovarian Neoplasm	Predictive	D	Supports Sensitivity Response	2	submitted	EID9852 In this preclinical study, high MDM2 expressing human ovarian cancer cell lines (OVTOKO and OVMANA) exhibited resistance to t-killing cells with a dead/live ratio of 4.2:1 and 1.9:1; (P = 0.03 and P =… (full text at CIViC) PMID 32655895 · Sahin et al., 2020 · Open in CIViC	civic
Cisplatin + PemetrexedCombination	Pleural Malignant MesotheliomaALIAS	Predictive	B	Supports Resistance	1	accepted	EID827 72 patients with malignant pleural mesothelioma were analyzed, MDM2 immunoexpression was assessed in 65 patients. MDM2 mRNA and protein expression correlated with poor OS and PFS for patients treated … (full text at CIViC) PMID 25668009 · Walter et al., 2015 · Open in CIViC	civic

MDM2 EXPRESSION3

(prognostic)

Pleural Malignant MesotheliomaALIAS

Prognostic

Supports Poor Outcome

accepted

EID828

72 patients with malignant pleural mesothelioma were analyzed, MDM2 immunoexpression was assessed in 65 patients. MDM2 mRNA and protein expression correlated with poor OS and PFS for patients treated … (full text at CIViC)

PMID 25668009 · Walter et al., 2015 · Open in CIViC

civic

Navtemadlin

Malignant Ovarian Neoplasm

Predictive

Supports Sensitivity Response

submitted

EID9852

In this preclinical study, high MDM2 expressing human ovarian cancer cell lines (OVTOKO and OVMANA) exhibited resistance to t-killing cells with a dead/live ratio of 4.2:1 and 1.9:1; (P = 0.03 and P =… (full text at CIViC)

PMID 32655895 · Sahin et al., 2020 · Open in CIViC

civic

Cisplatin + PemetrexedCombination

Pleural Malignant MesotheliomaALIAS

Predictive

Supports Resistance

accepted

EID827

PMID 25668009 · Walter et al., 2015 · Open in CIViC

civic

MDM2 RS348863281
(prognostic)	Esophageal Squamous Cell CarcinomaALIAS	Prognostic	B	Supports Better Outcome	2	accepted	EID1636 124 esophageal squamous cell carcinoma patients with radical resection were genotyped using MassArray. Patients with the DEL/A +AA genotype of MDM2 rs34886328 had a notably increased overall survival… (full text at CIViC) PMID 27414035 · Li et al., 2016 · Open in CIViC	civic

MDM2 RS348863281

(prognostic)

Esophageal Squamous Cell CarcinomaALIAS

Prognostic

Supports Better Outcome

accepted

EID1636

124 esophageal squamous cell carcinoma patients with radical resection were genotyped using MassArray. Patients with the DEL/A +AA genotype of MDM2 rs34886328 had a notably increased overall survival… (full text at CIViC)

PMID 27414035 · Li et al., 2016 · Open in CIViC

civic

MDM2 SNP3091
(prognostic)	Malignant Head and Neck NeoplasmALIAS	Prognostic	B	Supports Poor Outcome	2	accepted	EID1169 66 HNSCC patients treated with chemoradiation were assessed for survival after a follow-up time of 10 years. Median OS was significantly shorter in patients with MDM2 SNP309 GG or GT genotypes compare… (full text at CIViC) PMID 26916894 · Vivenza et al., 2016 · Open in CIViC	civic

MDM2 SNP3091

(prognostic)

Malignant Head and Neck NeoplasmALIAS

Prognostic

Supports Poor Outcome

accepted

EID1169

66 HNSCC patients treated with chemoradiation were assessed for survival after a follow-up time of 10 years. Median OS was significantly shorter in patients with MDM2 SNP309 GG or GT genotypes compare… (full text at CIViC)

PMID 26916894 · Vivenza et al., 2016 · Open in CIViC

civic